Healthy people: active immunization against chickenpox from the completion of 9 months. The vaccine is also recommended in healthy people who are in close contact with patients at risk of severe varicella disease in order to reduce the risk of smallpox virus transmission to these patients. This applies to parents and siblings of high-risk groups and other people who are in close contact with them, as well as medical and paramedical staff. Patients in high-risk groups - a vaccine recommended for active immunization of people who are particularly susceptible to infection and at risk of severe course of varicella: patients with leukemia during a full hematological remission (when the total lymphocyte count is at least 1200 / mm3 and there are no other disorders of cellular immunity), patients undergoing immunosuppressive therapy (including corticosteroids) due to solid malignancies or severe chronic diseases (such as chronic renal failure, autoimmune diseases, collagenosis, severe bronchial asthma) if the total number of lymphocytes is at least 1200 / mm3 and there are no other disorders of cellular immunity, patients qualified for organ transplantation (vaccination is recommended for a few weeks before starting immunosuppressive therapy), patients with chronic diseases (metabolic or endocrine disorders, chronic cardiovascular or respiratory diseases, cystic fibrosis, neuromuscular disorders) .
Composition:
1 dose (0.5 ml) contains not less than 2,000 PFU live, attenuated virusesVaricella zoster (Oka strain).
Action:
Vaccine against chickenpox, containing virusesVaricella zoster Oka strain obtained by propagation of the virus on human diploid cells of the MRC5 line. In non-immune patients, administration of the vaccine causes the clinically asymptomatic form of chickenpox. It is possible to obtain some immunity if the vaccine is used within 72 hours of contact with the patient. In healthy children vaccinated at the age of 9 months-12 years, in 6 weeks after vaccination, the total percentage of seroconversion was above 98%. In children vaccinated at 12-15 months the presence of antibodies has been demonstrated for at least 7 years after vaccination. In healthy subjects vaccinated above 13 years, the seroconversion rate was 100% in 6 weeks after the second dose of vaccine. One year after vaccination, antibodies were found in all vaccinated patients. In patients belonging to high-risk groups, the total seroconversion rate was 80%, in patients with leukemia - around 90%.
Contraindications:
Hypersensitivity to the components of the preparation. Systemic hypersensitivity to neomycin, but neomycin-associated contact dermatitis, is not a contraindication. Primary or acquired immunodeficiencies (ie leukemia, lymphoma, abnormal blood morphology, clinical signs of HIV infection or treatment with immunosuppressants, including high-dose corticosteroids) in patients with a total lymphocyte count below 1200 / mm3 or other signs of cellular immunity. Pregnancy (pregnancy should be avoided for 3 months after vaccination).
Precautions:
Do not administer intravascularly or intradermally. Do not use in acute and severe febrile illness (in healthy people a mild infection is not a contraindication to administering a vaccine).
Pregnancy and lactation:
Administration of the vaccine is contraindicated during pregnancy and pregnancy should be prevented for 3 months after vaccination. There are no data on the use of the vaccine during breastfeeding.
Side effects:
Very often: pain, redness. Common: rash, swelling at the injection site, fever (measured under the armpit or in the mouth ≥37,5 deg., Measured at the rectal ≥38st.C). Uncommon: upper respiratory tract infection, pharyngitis, generalized enlargement of the lymph nodes, irritability, headache, drowsiness, cough, rhinitis, nausea, vomiting, rash occurring in the course of chickenpox, pruritus, pain in the joints and muscles, fever (measured under the armpit or in the mouth> 39st.C, measured in the anus> 39.5st.C), tiredness, feeling unwell. Rarely: conjunctivitis, abdominal pain, diarrhea, urticaria. There was a tendency for more pain, redness and edema to occur after the second dose compared to the first dose.Adverse reactions reported post-marketing: shingles, hypersensitivity, anaphylactic reactions, convulsions, cerebellar ataxia.
Dosage:
Subcutaneously in the upper, side part of the arm. Patients from 9 months of age: 2 doses of vaccine (0.5 ml) given at least 6 weeks apart between vaccinations. Patients belonging to high-risk groups may need additional doses of the vaccine. 1 dose of the vaccine can be given to people who have already received one dose of another vaccine containing chickenpox. One dose of another vaccine containing varicella virus may be given after 1 dose of vaccine.
(C)
